Adult Acute Myeloid Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Myeloid Leukemia
Conditions
Brief summary
This phase I trial is studying the side effects and best dose of 5-Fluoro-2'-deoxycytidine (FdCyd) when given together with tetrahydrouridine (THU) in treating patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). FdCyd may inhibit cancer cell growth by increasing the production in cells of compounds that suppress growth or by otherwise killing cells. Although FdCyd is stable as a drug solution, it is rapidly inactivated by an enzyme present in people. THU is included in the treatment to inhibit the enzyme, prolonging the time FdCyd remains in the body
Detailed description
OBJECTIVES: I. Determine the maximum tolerated dose (MTD) of FdCyd administered with a fixed dose of THU in patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS), once daily on days 1-10 of a 21-day treatment cycle. II. To describe the toxicities of FdCyd/THU in patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). III. To document all clinical responses and hematologic improvement in patients treated with FdCyd/THU. IV. To obtain preliminary information regarding the effect of FdCyd/THU on deoxyribonucleic acid (DNA) methylation patterns in peripheral blood mononuclear cells and bone marrow aspirates, including malignant myeloid cells; the ratio of gamma- to beta-globin messenger ribonucleic acid (mRNA) in blood cells; and serum cytokines. OUTLINE: This is a dose-escalation study of FdCyd. Patients receive FdCyd intravenously (IV) over 3 hours and THU IV over 3 hours on days 1-10. Courses repeat every 21days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 4 weeks.
Interventions
DRUG5-fluoro-2-deoxycytidine
Given IV
Given IV
OTHERlaboratory biomarker analysis
Correlative studies
GENETICreverse transcriptase-polymerase chain reaction
Correlative studies
GENETICDNA methylation analysis
Correlative studies
Sponsors
City of Hope Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients must have the following diagnosis: * Acute myeloid leukemia * Relapsed or refractory * Newly diagnosed in patients age 60 and above or of any age unable to receive standard induction regimen * Patients with MDS with an International Prognostic Scoring System (IPSS) score \>= 0.5 * Newly diagnosed * Relapsed or refractory * Any prior therapy must have been completed \>= 2 weeks prior to enrollment and the participant must have recovered to eligibility levels from prior toxicity * No limit to number of prior regimens * Hydroxyurea is allowed prior to enrollment to keep white blood cell count (WBC) below 20 K * Valproic acid not being used for seizure control should be stopped 72 hours before starting therapy * Prior therapy with hypomethylating agent (decitabine or azacitidine) is allowed and must be completed \>= 6 weeks prior to enrollment * Relapsed patients are eligible post allogeneic or matched unrelated donor (MUD) transplant after 100 days; there should be no active acute graft versus host disease of any grade and patient should not be receiving immunosuppression for acute graft versus host disease; the patient must not have Chronic Graft versus Host disease (cGvHD) other than mild skin, oral, or ocular cGvHD not requiring systemic immunosuppression * Relapsed patients are eligible post autologous transplant after 100 days post transplant, with recovery of their counts absolute neutrophil count (ANC) \> 1000 and platelets greater than 75K at some point post transplant * Karnofsky performance status \>= 60% * Total bilirubin \< 1.5 x institutional upper limit of normal * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) =\< 2.5 x institutional upper limit of normal * Creatinine \< 1.5 x institutional upper limit of normal OR creatinine clearance \>= 60 mL/min for patients with creatinine levels above 1.5 x institutional upper limit of normal * Pregnant women will be excluded from this trial; nursing women are also excluded; women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for 3 months after completion of study; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately * Ability to understand and the willingness to sign a written informed consent document * Patients should not be receiving any other investigational agents
Exclusion criteria
* Patients with clinically significant illnesses which would compromise participation in the study, including, but not limited to: active or uncontrolled infection, immune deficiencies or confirmed diagnosis of human immunodeficiency virus (HIV) infection, active Hepatitis B, active Hepatitis C, or uncontrolled diabetes, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, uncontrolled cardiac arrhythmia; or psychiatric illness/social situations that would limit compliance with study requirements * Patients with additional (other than AML/MDS) currently active primary malignancy other than curatively treated carcinoma in situ (CIS) of the cervix, or basal or squamous cell carcinoma of the skin; patients are not considered to have a currently active malignancy if they have completed therapy for a prior malignancy and disease free from prior malignancies for \> 2 years * Patients with active central nervous system (CNS) disease; these patients are excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events * Active infections, including opportunistic following allo, MUD, or auto transplant (including but not limited to cytomegalovirus \[CMV\], fungal infection etc)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MTD and dose-limiting toxicity (DLT) of the new 10-day schedule of FdCyd/THU | 10 days | Toxicities will be summarized by Common Terminology Criteria for Adverse Events (CTCAE) grade and attribution using the version current at the initiation of the protocol. |
Secondary
| Measure | Time frame |
|---|---|
| Toxicities of the FdCyd/THU treatment | 3 years |
| Time to progression | 3 years |
| Overall survival | 3 years |
Countries
United States
Outcome results
None listed